NHS
Warwickshire North
Clinical Commissioning Group

Hysterectomy for Menorrhagia

VERSION CONTROL

Version:	3.0
Ratified by:	Governing Body Meetings in Common
Date ratified:	20 March 2019
Name of originator/author:	Joint CCG Clinical Commissioning Policy Development Group/NHS England
Name of responsible committees:	Clinical Quality and Governance Committee
Date issued:	1 April 2019
Review date:	March 2022

VERSION HISTORY

Date	**Version**	**Comment / Update**
	1.0	
March 2016	2.0	Approved by Governing Body
March 2019	3.0	Approved by Governing Body meetings in common

Commissioning policy: Warwickshire North CCG (WNCCG)

Evidence-Based Intervention Commissioning policy:

Hysterectomy for Menorrhagia

Treatment	Hysterectomy for Menorrhagia
Indication	Heavy menstrual bleeding (HMB)
Background	It is important that healthcare professionals understand what matters most to each woman and support her personal priorities and choices. Hysterectomy should be considered **ONLY** when: other treatment options have failed, are contradicted; there is a wish for amenorrhoea (no periods); the woman (who has been fully informed) requests it; the woman no longer wishes to retain her uterus and fertility.
Treatment:	***1.13.1.1.1 NICE guideline NG88 1.5 Management of HMB*** 1.5.1 When agreeing treatment options for HMB with women, take into account: the woman's preferences, any comorbidities, the presence or absence of fibroids (including size, number and location), polyps, endometrial pathology or adenomyosis, other symptoms such as pressure and pain. ***1.13.1.1.2 Treatments for women with no identified pathology, fibroids less than 3 cm in diameter, or suspected or diagnosed adenomyosis*** 1.5.2 Consider an LNG-IUS (levonorgestrel-releasing intrauterine system) as the first treatment for HMB in women with: no identified pathology or fibroids less than 3 cm in diameter, which are not causing distortion of the uterine cavity or suspected or diagnosed adenomyosis. 1.5.3 If a woman with HMB declines an LNG-IUS or it is not suitable, consider the following pharmacological treatments: non-hormonal: tranexamic acid, NSAIDs (non-steroidal anti-inflammatory drugs), hormonal: combined hormonal contraception, cyclical oral progestogens. 1.5.4 Be aware that progestogen-only contraception may suppress menstruation, which could be beneficial to women with HMB. 1.5.5 If treatment is unsuccessful, the woman declines pharmacological treatment, or symptoms are severe, consider referral to specialist care for: investigations to diagnose the cause of HMB, if needed, taking into account any investigations the woman has already had and alternative treatment choices, including: pharmacological options not already tried (see recommendations 1.5.2 and 1.5.3), surgical options: second-generation endometrial ablation, hysterectomy. 1.5.6 For women with submucosal fibroids, consider hysteroscopic removal. ***1.13.1.1.3 Treatments for women with fibroids of 3 cm or more in diameter*** 1.5.7 Consider referring women to specialist care to undertake additional investigations and discuss treatment options for fibroids of 3 cm or more in

	diameter. 1.5.8 If pharmacological treatment is needed while investigations and definitive treatment are being organised, offer tranexamic acid and/or NSAIDs. 1.5.9 Advise women to continue using NSAIDs and/or tranexamic acid for as long as they are found to be beneficial. 1.5.10 For women with fibroids of 3 cm or more in diameter, take into account the size, location and number of fibroids, and the severity of the symptoms and consider the following treatments: pharmacological: non-hormonal: tranexamic acid, NSAIDs, hormonal: LNG-IUS, combined hormonal contraception, cyclical oral progestogens, uterine artery embolization, surgical: myomectomy, hysterectomy. 1.5.12 Be aware that the effectiveness of pharmacological treatments for HMB may be limited in women with fibroids that are substantially greater than 3 cm in diameter. 1.5.13 Prior to scheduling of uterine artery embolisation or myomectomy, the woman's uterus and fibroid(s) should be assessed by ultrasound. If further information about fibroid position, size, number and vascularity is needed, MRI should be considered. [2007] 1.5.14 Consider second-generation endometrial ablation as a treatment option for women with HMB and fibroids of 3 cm or more in diameter who meet the criteria specified in the manufacturers' instructions. 1.5.15 If treatment is unsuccessful: consider further investigations to reassess the cause of HMB, taking into account the results of previous investigations and offer alternative treatment with a choice of the options described in recommendation 1.5.10. 1.5.16 Pre-treatment with a gonadotrophin-releasing hormone analogue before hysterectomy and myomectomy should be considered if uterine fibroids are causing an enlarged or distorted uterus. **Prior approval from the Clinical Commissioning Group will be required before any treatment proceeds in secondary care.**
Diagnostic & Procedure Codes	Q072, Q074, Q075, Q078, Q079, Q081, Q082, Q083, Q088, Q089, N920
Equality Impact	See NHS England Equality and Health Inequalities – Full Analysis Form